Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

2.320
-0.040-1.69%
Volume:14.77M
Turnover:33.92M
Market Cap:9.27B
PE:18.49
High:2.350
Open:2.350
Low:2.260
Close:2.360
52wk High:4.490
52wk Low:1.670
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:1.12
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.125
ROE:3.68%
ROA:2.41%
PB:0.55
PE(LYR):18.49
PS:1.32

Loading ...

Luye Pharma - Certain Units Entered Agreement With Jiangsu Nhwa Hexin Pharmaceutical Marketing

THOMSON REUTERS
·
Dec 24, 2025

Luye Pharma - Grant of Commercialization Rights to Nhwa for 3 Long-Acting Injectable Antipsychotics in China

THOMSON REUTERS
·
Dec 24, 2025

Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China

Reuters
·
Dec 24, 2025

Luye Pharma Unit Completes Sale of Boan Biotech-Linked Exchangeable Shares

MT Newswires Live
·
Dec 15, 2025

LUYE PHARMA Subsidiary Completes Issuance of 1.5 Million Exchangeable Preferred Shares

Deep News
·
Dec 15, 2025

Luye Pharma Group (SEHK:2186): Valuation Check After New Exchangeable Preference Share Deal in Boan Biotech

Simply Wall St.
·
Dec 14, 2025

LUYE PHARMA (02186) Subsidiary Completes Issuance of 1.5 Million Exchangeable Preferred Shares

Stock News
·
Dec 12, 2025

Luye Pharma Subsidiary Issues Exchangeable Preference Shares to Bluebell Asset Holding

Reuters
·
Dec 12, 2025

Private companies are Luye Pharma Group Ltd.'s (HKG:2186) biggest owners and were hit after market cap dropped HK$639m

Simply Wall St.
·
Dec 12, 2025

Luye Pharma Says Five New Products Added to China's Drug Reimbursement List

MT Newswires Live
·
Dec 08, 2025

HK Stock Movement | LUYE PHARMA (02186) Rises Nearly 3% as Five New Products Including Mimexin® Included in National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory

Stock News
·
Dec 08, 2025

LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory

Stock News
·
Dec 07, 2025

Southbound Capital Flow Data (T+2) for Hong Kong Stocks | November 27

Stock News
·
Nov 27, 2025

HK Stock Movement | LUYE PHARMA (02186) Rises Over 3% as New Drug LY03017 Approved for Clinical Trials in the U.S. Targeting PDP and Other Conditions

Stock News
·
Nov 26, 2025

Luye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017

Reuters
·
Nov 24, 2025

Luye Pharma Gets U.S. FDA Nod to Start Trials for New CNS Drug

MT Newswires Live
·
Nov 24, 2025

BRIEF-Luye Pharma Says Approval Obtained For LY03017 For Clinical Trials In U.S.

Reuters
·
Nov 24, 2025

LUYE PHARMA (02186) Receives FDA Approval for Clinical Trials of New Drug LY03017 in the U.S.

Stock News
·
Nov 24, 2025

Luye Pharma (02186) Gains U.S. FDA Clearance for CNS Drug LY03017

Bulletin Express
·
Nov 24, 2025

Luye Pharma - Approval Obtained for Group's New Drug Ly03017 for Clinical Trials in U.S.

THOMSON REUTERS
·
Nov 24, 2025